PetMed Express (NASDAQ:PETS) Posts Earnings Results, Misses Estimates By $0.45 EPS

PetMed Express (NASDAQ:PETS) posted its earnings results on Friday. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.45), reports. PetMed Express had a negative return on equity of 6.76% and a negative net margin of 2.76%.The company had revenue of $44.36 million during the quarter.

PetMed Express Price Performance

NASDAQ PETS opened at $3.60 on Friday. PetMed Express has a 1-year low of $1.57 and a 1-year high of $5.58. The business’s fifty day moving average price is $2.37 and its 200-day moving average price is $2.88. The stock has a market capitalization of $76.93 million, a price-to-earnings ratio of -12.00 and a beta of 0.75.

Hedge Funds Weigh In On PetMed Express

Institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its stake in PetMed Express by 5.4% in the third quarter. Dimensional Fund Advisors LP now owns 481,517 shares of the company’s stock valued at $1,209,000 after acquiring an additional 24,624 shares in the last quarter. Man Group plc lifted its holdings in shares of PetMed Express by 7.1% in the 3rd quarter. Man Group plc now owns 151,039 shares of the company’s stock valued at $379,000 after purchasing an additional 9,989 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of PetMed Express by 164.3% in the 3rd quarter. Bridgeway Capital Management LLC now owns 107,816 shares of the company’s stock valued at $271,000 after purchasing an additional 67,016 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of PetMed Express in the 3rd quarter valued at about $153,000. Finally, Goldman Sachs Group Inc. grew its stake in PetMed Express by 59.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company’s stock worth $139,000 after buying an additional 12,360 shares during the last quarter. Institutional investors and hedge funds own 73.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on PETS shares. Weiss Ratings restated a “sell (d)” rating on shares of PetMed Express in a report on Wednesday, October 8th. Wall Street Zen lowered PetMed Express from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th. Finally, Zacks Research raised PetMed Express from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. One analyst has rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Sell” and an average price target of $3.20.

About PetMed Express

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.